Figure 2. Time-prevalence chart for annual screening for 15–24-year-old women and a hypothetical chlamydia vaccine program for preadolescent girls (14 years of age) and women 15–24 years of age in the United States from the main analyses. We separated the start of the different programs (i.e., screening and vaccination) for illustrative purposes and to avoid clutter. When estimating the health and economic outcomes, we assumed that the strategy being analyzed started at the 20-year mark and the outcomes were tracked over a 50-year period (analytic horizon) ending at the 70-year mark. *Includes the existing annual screening (15–24-year-old women) strategy. Screening and vaccination coverage were 30% for all applicable age groups.